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(IPSS) in prostate cancer patients who received image-guided 
volumetric modulated arc therapy (IG-VMAT). 
Materials and Methods: From August 2008 to November 2011, 190 
consecutive prostate cancer patients were treated with IG-VMAT to a 
dose of 76 Gy with daily correction of the target position based on 
cone-beam CT imaging. The IPSS and Common Terminology Criteria 
for Adverse Events (CTCAE) version 4.0 toxicity were prospectively 
scored before VMAT, at the end of VMAT, 1, 3, 6, 12, 18, 24 and 36 
months after VMAT. IPSS resolution was defined as a return to within 1 
point of the score at baseline. Clinical, treatment-related parameters 
were evaluated included patient age, alpha-blocker use, androgen 
deprivation therapy (ADT) use, body mass index, diabetes, 
hypertension, smoking and drinking habits, and prostate volume. 
Dosimetric quality indicators were also examined. 
Results: The median follow-up was 24.2 months (range,11.3-47.6). 
134 (70.5%) patients took ADT medications. At last follow-up, 67 
(35.3%) patients took alpha-blocker medications. The 2-year actuarial 
rate of grade 2 or greater genitourinary toxicity was 2.6%. The median 
(inter-quartile range) IPSS before VMAT, at the end of VMAT, 1, 3 
months after VMAT and at last follow-up were 3(1-7), 9(5-12), 6(2-9), 
3(1-8), and 4(1-7), respectively. The IPSS returned to baseline at a 
median of 3.0 months. The IPSS of 49 patients (25.8%) didn't exceed 
baseline+2 throughout the follow up. In Cox regression analysis, only 
drinking habit was associated with increased IPSS exceed baseline+2 
(95% CI 0.283-0.907, p=0.022). 
Conclusions: In IG-VMAT, IPSS resolved within 3 months substantially, 
and late GU toxicity was very low. Cessation of drinking during 
radiotherapy may be useful for further improvement. 
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Purpose/Objective: Most researchers consider kidney cancer 
radioresistant and in light of this what seems to be the 'common 
knowledge' use of radiation therapy to treat those lesions is not 
effective. An analysis of traditional approach indicate the possibility 
of changing that dogma, aiming to of achieve positive results in the 
implementation of radiosurgical abilities to deliver ablative radiation 
doses by means of radiosurgical system CyberKnife. 
Materials and Methods: Fifty patients with medically inoperable renal 
cell cancer (RCC), (from October 2009 to December 2012) were 
treated with robotic SBRT CyberKnife modalities. Eighteen (18) of 
them were diagnosed with single kidney (RCC). All 18 patients had 
metastases from malignant kidney to contralateral kidney and three of 
them had metastases spread to brain, lung, and pancreas. 
Dose/fractionation schedules varied between 10 to 13 Gy per 
fractionand 3 to 4 sessions on kidney and 15 to 20 Gy, 1 to 3 sessions 
on other metastases depending on target location, and size. Tumor 
volume varied from 5 to 180 cc. Follow-up times for patients who 
remained alive were 6 to 25 months and for those who died 
(2patients) were 14 to17 months. 
Results: All eighteen patients were carefully followed by 
multidisciplinary team, contrasted CT scans, renal scintigraphy, and 
blood work was analyzed. Local controls defined as radiologically 
stable disease or partial/complete response was obtained in all 
eighteen patients with single kidney. A partial response as defined as 
a greater than 50% reductions tumor volume was noted in 12 patients. 
Kidney function remained unaffected after treatment in seventeen 
patients, the Creatinine levels remained normal, but one (slightly 
elevated up to 125 mmol/L). Parameters of the dynamic renal 
scintigraphy not affected by the radiosurgery. Side effects were mild, 
grade 1 in 8 cases. No patient was reported with grade 2 to 4 toxicity. 
No complications of the fiducial placement reported. 
Conclusions: The results show positive effect of treatment. These can 
be evaluated as an alternative to surgery and provide local control 
while maintaining the function of a single kidney. Stereotactic body 
radiationtherapy (SBRT), also known as stereotactic ablative 
radiotherapy (SABR), is emerging as one of the new treatment options 
for renal cell cancer (RCC) mainly in medically inoperable patients 
especially reducing surgical risks in patients with single remaining 
kidney.  
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Purpose/Objective: Dose escalation is known to improve outcomes in 
prostate cancer at the expense of a higher risk of side effects. Focal 
dose escalation, targeting the area most at risk of recurrence, may 
improve outcomes without increasing the burden of toxicity, 
especially as the majority of intra-prostatic recurrence occurs at the 
site of the dominant disease nodule at presentation. Fast dose fall-off 
with new radiotherapy techniques such as Cyberknife and Rapid Arc 
improves our ability to dose paint. 
Materials and Methods: Fifteen patients, who were previously treated 
with IMRT at our institution, and had dominant intra-prostatic disease 
nodules (DPDN) on MRI were selected. Their diagnostic MRI was fused 
with their radiotherapy planning CT and the DPDN was contoured with 
the assistance of an expert radiologist. For RapidArc plans, two PTV 
margins were employed: Cyberknife margins (5mm expansion of the 
prostate, except 3mm posteriorly) and larger margins (prostate + 
8mm/4mm posteriorly) in order to account for intra-fraction motion. 
Trial plans were constructed in order to deliver 36.25 Gy in 5 fractions 
to the PTV (as defined above) with a simultaneous integrated boost 
(SIB) of 47.5 Gy to the DPDN which was planned with no PTV margin. 
Minor relaxation of our usual SBRT dose constraints were allowed to 
facilitate the boost dose, as long as the plan was deemed clinically 
acceptable.  
Results: With 5/3mm margins, RapidArc and Multiplan wereboth able 
to produce SIB plans within constraints in most patients. Mean rectal 
D50% and D20% doses were lower for RapidArc compared with 
Multiplan (p=0.01 and 0.005 respectively) but the constraints were 
exceeded in approximately the same number of occasions. If the PTV 
(8/4mm) margin was increased, over half the tolerances were 
exceeded. 
 
Conclusions: Both RapidArc and Multiplan can produce clinically 
acceptable SIB plans, focally escalating to 47.5 Gy, within standard 
OAR constraints. However, if a margin large enough to account for 
intra-fraction motion is used, the RapidArc plans no longer meet the 
required dose constraints. Focal SIB treatments are feasible if intra-
fraction motion can be tracked and corrected.  
 
 POSTER: CLINICAL TRACK: GYNAECOLOGICAL 
TUMOURS  
  
PO-0732   
Clinical trial of carbon ion radiotherapy for gynecological melanoma 
K. Karasawa1, M. Wakatsuki1, T. Kamada1 
1National Institute of Radiological Sciences, Research Center Hospital 
for Charged Particle Therapy, Chiba-city, Japan  
 
Purpose/Objective: To evaluate a toxicity and efficacy of carbon ion 
radiotherapy for gynecological melanoma, we conducted a Phase I/II 
clinical trial. 
Materials and Methods: The eligibilitycriteria for enrollment in this 
study were (1) histologically proven malignantmelanoma, (2) a 
localized measurable tumor in gynecological region, (3) atleast a 5 
mm gap between the tumor and radiosensitive organs, including bowel 
and bladder, and (4) a expected prognosis of more than 6 months. 
Tumors were classifiedby TNM classification for malignant melanoma. 
In principle, tumors with PTV margins were irradiated 3.6 GyE per 
fraction up to the total dose of 57.6 GyE in 16 fractions, 4 times a 
week. Acute toxicities were assessed according to NCI-CTCAE ver.4.0 
within 3 months after the treatment. Treatment response was 
assessed at 3 month after treatment completion. Late toxicities were 
assessed according to RTOG/EORTC scoring system. Statistical analysis 
of local control and survival were calculated using the Kaplan-Meier 
method. 
Results: A series of 23 gynecological melanoma patients were treated 
with carbonion radiotherapy between November 2004 and October 
2012. The age ranged from 51 to 80 with a median of 71. The tumor 
 
2nd ESTRO Forum 2013   S277 
sites were vagina in 14, vagina and vulva in 4, uterine cervix in 3, and 
vulva in 2. The T stage was r2a in 2, 3a in 3, 4a in 17 and r4 in 1. The 
clinical stage was stage II in15, r stage II in 3, stage III in 4, and stage 
IV in 1. The irradiated dose was 57.6 GyE in 22 and 64 GyE in 1. 
Twelve patients were treated with DAV regime (DTIC, ACNU, VCR), 
and 8 patients were treated with IFN-β for induction and /or adjuvant 
therapy. One patient had been used IFN-β during radiotherapy. Acute 
toxicities greater than grade 2 were colitis in 4, diarrhea in 4, fecal 
incontinence in 1, malaise in 1,dermatitis radiation in 11, urinary 
frequency in 2, urinary infection in 1, urinary tract pain in 9, perineal 
pain in 10, and vaginal pain in 9. One patient who had been treated 
with concurrent IFN-β developed sepsis. The median follow-up time 
was 17 months (ranged 1 to 53 months). One case of grade 3 bowel 
reaction, one case of grade 2 bowel reaction, and one case of grade 3 
bladder reaction have been observed. Twelve patients have recurred, 
in-field in 3,marginal field in 2, regional lymph node in 4 and distant 
in 9. Ten patients were dead, two were of intercurrent disease and 
other 8 were of melanoma. The 2-year local control rate and overall 
survival rate were 80% and 56% respectively. 
Conclusions: Carbon ion radiotherapy for gynecological melanoma 
offered therapeutic effectiveness with acceptable toxicities of normal 
tissues. 
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Purpose/Objective: To investigate diffusion weighted imaging (DWI) 
as an imaging biomarker in women undergoing chemoradiation for 
vault cancers. 
Materials and Methods: From October 2008 to May, 2012 patients 
scheduled to undergo chemoradiation and vaginal brachytherapy for 
vault cancers were included. All underwentT2-Weighted (T2W) and 
DWI before chemoradiation. Gross tumor volume (GTV), lateral 
extent, apparent diffusion coefficient (ADC) and presence of regions 
of focally restricted diffusion (or intratumoral diffusion heterogeneity) 
were determined at baseline. Immediate response to chemoradiation 
was categorised as either partial or complete and long term response 
as local relapse /disease free or not. Receiver Operator 
Characteristics (ROC) curve identified thresholds of GTV and ADC that 
best predict for partial response. Data was categorized across 
identified cut off’s for univariate and cox multivariate regression 
analysis in SPSS version 15.0.  
Results: The study included 29 patients with a median follow up of 16 
months (3-35 months).The median GTV was 27 cc (3.4-110cc). Central 
and lateral disease was present in 13(44.8%) and 16 (55.2%) patients 
respectively. The median ADC was 1.1x 10 -3 mm2/sec (0.75-1.37X10 -3 
mm2/sec) and 12/29 (41.3%) patients had focal regions of restricted 
diffusion. All received concurrent chemoradiation to a dose of 50 
Gy/25#/5 weeks with concurrent cisplatin. This was followed by 
interstitial brachytherapy (20Gy/5#/3 days). Overall 16/29 (55.1%) 
patients had radiological partial response at 50 Gy. At a median follow 
up of 16 months, 20/29 (68.9%) patients were disease free and 21/29 
(72.4%) were without local recurrence. On univariate analysis bulky 
disease (81.8%vs. 35.2%; p=0.01), lateral disease extent (75% vs. 
30.7%; p=0.01) predicted for partial response at completion of 
treatment. However on multivariate analysis only ADC value >1 x10-3 
mm2/s predicted for partial response (63.1% vs 33.1%; p=0.02). On 
multivariate analysis in addition to tumour bulk (p=0.01), focal regions 
of ADC restriction were identified as an independent factor impacting 
long-term local relapse free (p=0.01) and disease free survival 
(p=0.01) 
Conclusions: Tumor ADC and intratumoral focal regions of restricted 
diffusion independently predict for partial response and reduced local 
relapse free and disease free survival in women undergoing 
chemoradiation for vault cancers. Results of the study need validation 
in larger cohort. 
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Purpose/Objective: Metastatic lymph nodes (LN) are one of the most 
important prognostic factors for cervical cancer patients (PTS). The 
standard prescribed radiotherapy dose fails to successfully control the 
nodal disease and the dose escalation with conventional techniques is 
connected with dose limiting toxicities. The aim of this study is to 
evaluate dosimetric parameters and early and late toxicities of dose 
escalated intensity modulated radiotherapy (IMRT). 
Materials and Methods: The study included cervical cancer PTS with 
PET-CT positive LN treated with escalated dose of RT with curative 
intent. The dose of 50.4 Gy (1.8 Gy daily) was prescribed to the 
elective nodal volume and gross tumor volume. In case of positive LN 
in level of the arteria Iliaca communis the dose of 45 Gy was 
prescribed to the paraaortic region and in case of involved paraaortic 
LN dose was 50.4 Gy (Phase I). Primary tumors < 4 cm in diameter 
received boost of 5.4 Gy and for those > 4 cm in diameter a boost of 9 
Gy (Phase II). PET-CTpositive LN received consecutive boost to total 
dose of 59.4 Gy, or simultaneous integrated boost (SIB) to a total dose 
of 62 Gy. IMRT was followed by 3D conformal HDR intrauterine 
brachytherapy with a single fraction of 6 Gy to a total dose of 18 Gy. 
We evaluated summed Dose Volume Histograms (DVH) data for all 
patients.Toxicities were graded according to the CTCAE v3.0. 
Results: In period between Oct. 2006 and Feb. 2012, 21 PTS with 
median age of 63 Y (range: 48-101Y) were treated. 16 PTS had tumor 
> 4cm and median number of positive LN pro patient was 3 (range: 1-5 
LN). 8 PTS were diagnosed with positive paraaortic LN. 12 PTS were 
treated with extended field RT. 14 patients received SIB and 7 
consecutive boost to the positive LN. 2 PTS received IMRT boost to 
primary tumor of 72 Gy. Median follow-up time was 25 months (range: 
5-51months). 20 PTS received concomitant weekly cisplatine 
chemotherapy. Median bladder volume was 127 cm3 (range: 20-591 
cm3) with median dose to the organ of 52 Gy. Median intestine 
volume was 1840 cm3 (range:1000-4798 cm3) with median dose to the 
organ of 21 Gy. Median rectal volume was 75 cm3 (range: 23-250 cm3) 
with median dose to the organ of 53 Gy. Median ratios of total 
structure volumes (DVH parameters of summed plans) with 
corresponding doses are showed in Table 1. Median PTV volume for 
phase I, phase II and nodal boost were 1431 cm3(range: 1037-2248 
cm3), 461 cm3 (range: 216-961cm3) and 37 cm3 (range: 5-201cm3) 
respectively. The therapy was well tolerated. We record no toxicities 
from side upper GIT, rectum, bladder and vagina in 38%, 86%, 76% and 
81% PTS respectively.Two PTS developed acute toxicities grade 3 (1 
acute diarrhea and 1 cystitis). One patient has vaginal dryness grade 3 
as a late sequel of RT. There were no toxicities greater than grade 3. 
 
Table 1. Median DVH Parameters of summed plans – Median 
Volume Percentage (Range) 
 V20  V30 V40 V50 V60 
Bladder 100 (88-
100) 
97 (71-
100) 
82 (82-
100) 
58 (14-
98) 
0 (0-39) 
Rectum 99 (89-100) 97 (88-
100) 
86 (75-
100) 
65 (13-
95) 
0 (0-45) 
Intestine 52 (29-74) 29 (15-42) 16 (5-31) 8 (0-19) 0 (0-2) 
 
Conclusions: The dose escalation is feasible and seems to have a 
satisfactory profile of toxicities. We succeed to fulfill the dose 
constraints comparable with those in the literature.  
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Purpose/Objective: 3D image based treatment planning has allowed 
examination of dose volume parameters rather than point doses in 
intracavitary brachytherapy (ICBT) of cervical cancer. The degree of 
bladder distension may change doses to organs at risk (OARs) & 
thereby incidence of complications. The purpose of the study was to 
assess impact of bladder volume on OARs wall doses during ICBT of 
cervical cancer patients. 
Materials and Methods: A prospective study performed in 10 patients 
with cervix cancer, stages II-III, treated by HDR-ICBT 600cGy / 
fraction for 3 fractions to Point A using conventional radiography 
based treatment planning. For dosimetric study all patients after 
insertion of ICBT applicator underwent pelvic CT scans with foley’s 
catheter in place (defined as empty bladder, EB) & thereafter 
injecting 300ml of normal saline in bladder, defined as full bladder 
